Pioneering proteomics

Join us at AACR 2023 to learn how you can discover
more biological insights into cancer with the power of proteomics

Be the first to discover meaningful insights
and key targets

We look forward to meeting you in
Orlando from April 14-18.

Stop by Booth 1618 to learn how the power of our 7,000-plex menu is the single, scalable platform that can transform your cancer research.

Not attending? Or want to know more today? Contact us!


Accelerating Precision Medicine of Cancer with SomaScan® Proteomics

Tuesday, April 18, 2023 | 3:00-4:00 PM
Exhibitor Spotlight Theater

Presenter: Towia Libermann, PhD
Associate Professor of Medicine
Beth Israel Deaconess Medical Center
Harvard Medical School

Join us Tuesday afternoon for a discussion about how proteomics has emerged as the next frontier in precision medicine. Towia Libermann, PhD, will present findings on using the SomaScan Platform to discover and independently validate diagnostic, predictive, and prognostic biomarkers for various cancers.

Protein biomarker efforts for early detection of liver cancer and for predicting response to immunotherapy in metastatic melanoma will be presented.

This Exhibitor Spotlight Theater is a promotional activity and is not approved for continuing education credit. The content of this Exhibitor Spotlight Theater and opinions expressed by presenters are those of the sponsor or presenter and are not of the American Association for Cancer Research (AACR).

AACR 2023 poster sessions

Download our AACR 2023 Poster Session Postcard for quick reference.
Visit this page after the sessions to view the posters online.

P38.04The plasma proteome
as a cardiovascular risk assessment tool in cancer survivors

Presenter: Jessica Kuzma, PhD
Scientist II
Clinical Research and Development

See poster

P32.27Efficient development of prognostic tests for detecting cancer risk using proteomic technology

Presenter: Yolanda Hagar, PhD
Associate Director,

See poster

Enhance your data by adding the
SomaScan Platform to your cancer research

With only a 55-μL sample of serum or plasma, the SomaScan Platform is transforming cancer research in four fundamental ways:

  • Diagnostic
  • Prognostic
  • Predictive
  • Stratification

Image of SomaScan Assay video detailing how the Assay works

What if you could discover more biomarkers and predict disease progression?

Learn more
Talk to us today

Want a quick look at how the SomaScan Assay works?

Our Slow Off-Rate Modified Aptamers (called SOMAmer® reagents) are custom-engineered to have exquisite shape complementarity to their protein targets. Put them into action with a single, 55-μL sample.


Accelerate your research,
or generate revenue as a service provider

Learn how you can run the SomaScan Assay within your own lab. As a SomaLogic Authorized Site, you will not only receive the benefits of analyzing your samples in-house, but can also accelerate your workflow, automate your processes, and unlock revenue-generating capabilities. And our expert support team will assist you every step of the way.

Thumbnail image of Dr Richard Head from Washington Medical University

Hear how Washington University uses the SomaScan® Assay on-site in their own lab for greater efficiency and deeper insights.

Watch now